BRPI0011674B8 - cristal de (r)-2-[[[3-metil-4-(2,2,2-trifluoroetóxi)-2-piridinil]metil] sulfinil]-1h-benzimidazol, composição farmacêutica, e, uso do referido cristal - Google Patents

cristal de (r)-2-[[[3-metil-4-(2,2,2-trifluoroetóxi)-2-piridinil]metil] sulfinil]-1h-benzimidazol, composição farmacêutica, e, uso do referido cristal

Info

Publication number
BRPI0011674B8
BRPI0011674B8 BRPI0011674A BR0011674A BRPI0011674B8 BR PI0011674 B8 BRPI0011674 B8 BR PI0011674B8 BR PI0011674 A BRPI0011674 A BR PI0011674A BR 0011674 A BR0011674 A BR 0011674A BR PI0011674 B8 BRPI0011674 B8 BR PI0011674B8
Authority
BR
Brazil
Prior art keywords
crystal
methyl
trifluoroethoxy
sulfinyl
pyridinyl
Prior art date
Application number
BRPI0011674A
Other languages
English (en)
Other versions
BR0011674A (pt
BRPI0011674B1 (pt
Inventor
Fujishima Akira
Aoki Isao
Kamiyama Keiji
Original Assignee
Takeda Chemical Industries Ltd
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=15924444&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0011674(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Chemical Industries Ltd, Takeda Pharmaceuticals Co filed Critical Takeda Chemical Industries Ltd
Publication of BR0011674A publication Critical patent/BR0011674A/pt
Publication of BRPI0011674B1 publication Critical patent/BRPI0011674B1/pt
Publication of BRPI0011674B8 publication Critical patent/BRPI0011674B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"cristal, composição farmacêutica, método para tratar ou prevenir úlcera digestiva em um mamífero em necessidade deste, e, uso do cristal". um novo cristal de (r)-2-[[[3-metil-4-(2,2,2-trifluoroetóxi)-2-piridinil]metil]sulfinil]-1h-benzimidazol ou um sal deste da presente invenção é útil para um excelente agente anti-ulcerativo.
BRPI0011674A 1999-06-17 2000-06-15 cristal de (r)-2-[[[3-metil-4-(2,2,2-trifluoroetóxi)-2-piridinil]metil] sulfinil]-1h-benzimidazol, composição farmacêutica, e, uso do referido cristal BRPI0011674B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP17150999 1999-06-17
PCT/JP2000/003880 WO2000078745A2 (en) 1999-06-17 2000-06-15 Crystalline form of (r)-2-[[[3-methyl- 4- (2,2,2,- trifluoroethoxy) -2- pyridinyl] methyl] sulfinyl] -1h-benzimidazole

Publications (3)

Publication Number Publication Date
BR0011674A BR0011674A (pt) 2002-03-19
BRPI0011674B1 BRPI0011674B1 (pt) 2017-05-30
BRPI0011674B8 true BRPI0011674B8 (pt) 2021-05-25

Family

ID=15924444

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0011674A BRPI0011674B8 (pt) 1999-06-17 2000-06-15 cristal de (r)-2-[[[3-metil-4-(2,2,2-trifluoroetóxi)-2-piridinil]metil] sulfinil]-1h-benzimidazol, composição farmacêutica, e, uso do referido cristal

Country Status (27)

Country Link
US (11) US6462058B1 (pt)
EP (3) EP1129088B1 (pt)
KR (3) KR100537029B1 (pt)
CN (1) CN1150186C (pt)
AR (5) AR031069A1 (pt)
AT (1) ATE391126T1 (pt)
AU (1) AU778820B2 (pt)
BE (1) BE2014C017I2 (pt)
BR (1) BRPI0011674B8 (pt)
CA (1) CA2375201C (pt)
CY (2) CY1110384T1 (pt)
DE (1) DE60038481T2 (pt)
DK (2) DK1977751T3 (pt)
ES (2) ES2300265T3 (pt)
HK (2) HK1038227A1 (pt)
HU (1) HU229067B1 (pt)
IL (2) IL145996A0 (pt)
MX (1) MXPA01012642A (pt)
MY (1) MY125399A (pt)
NO (1) NO321168B1 (pt)
NZ (1) NZ515702A (pt)
PL (1) PL201068B1 (pt)
PT (2) PT1129088E (pt)
SI (1) SI1129088T1 (pt)
TW (2) TWI289557B (pt)
WO (2) WO2004083200A1 (pt)
ZA (1) ZA200108331B (pt)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US20040224989A1 (en) * 1999-01-29 2004-11-11 Barberich Timothy J. S-lansoprazole compositions and methods
TWI289557B (en) * 1999-06-17 2007-11-11 Takeda Chemical Industries Ltd A crystal of a hydrate of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
WO2001002389A1 (fr) * 1999-06-30 2001-01-11 Takeda Chemical Industries, Ltd. Cristaux de composes benzimidazole
CN1193024C (zh) 2000-04-28 2005-03-16 武田药品工业株式会社 生产旋光的亚砜衍生物的方法
KR101035534B1 (ko) * 2000-05-15 2011-05-23 다케다 야쿠힌 고교 가부시키가이샤 결정의 제조방법
CA2417311C (en) 2000-08-04 2012-07-10 Takeda Chemical Industries, Ltd. Crystalline alkali metal salts of lansoprazole and their production and use
KR100887912B1 (ko) 2000-12-01 2009-03-12 다케다 야쿠힌 고교 가부시키가이샤 (ｒ)- 또는 (ｓ)-란소프라졸의 결정화 방법
CN100562317C (zh) 2001-10-17 2009-11-25 武田药品工业株式会社 含大量酸不稳定药物的颗粒
KR100467100B1 (ko) * 2002-03-20 2005-01-24 일양약품주식회사 2-[(4-메톡시-3-메틸)-2-피리디닐]메틸설피닐-5-(1Ｈ-피롤-1-릴)-1Ｈ-벤즈이미다졸 또는 이의 Ｎа염을 함유하는주사제의 제조방법
KR20040093187A (ko) * 2002-03-27 2004-11-04 테바 파마슈티컬 인더스트리즈 리미티드 란소프라졸 다형 및 그것의 제조 방법
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
US8697094B2 (en) * 2002-10-16 2014-04-15 Takeda Pharmaceutical Company Limited Stable solid preparations
US20050220870A1 (en) * 2003-02-20 2005-10-06 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
EP1607395B1 (en) * 2003-03-24 2011-05-04 Eisai R&D Management Co., Ltd. Process for the preparation of amorphous rabeprazole sodium salt
CA2529255A1 (en) * 2003-06-20 2004-12-29 Ch Chemicals (Pty) Ltd Polyurethane-based cementitious liner
JP2006528181A (ja) * 2003-07-18 2006-12-14 サンタラス インコーポレイティッド 酸分泌を阻害するために有用な薬学的製剤ならびにそれらを作製および使用する方法
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
AU2004257864A1 (en) * 2003-07-18 2005-01-27 Santarus, Inc. Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
JP2007522217A (ja) * 2004-02-10 2007-08-09 サンタラス インコーポレイティッド プロトンポンプ阻害剤、緩衝剤および非ステロイド系抗炎症薬の組み合わせ
CA2561700A1 (en) * 2004-04-16 2005-12-15 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and prokinetic agent
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
JP5563735B2 (ja) 2004-06-16 2014-07-30 タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド Ｐｐｉ多回剤形
JP5173191B2 (ja) 2004-09-13 2013-03-27 武田薬品工業株式会社 酸化化合物の製造方法及び製造装置
WO2006090845A1 (ja) 2005-02-25 2006-08-31 Takeda Pharmaceutical Company Limited 顆粒の製造方法
ES2259269B1 (es) 2005-03-03 2007-11-01 Esteve Quimica, S.A. Procedimiento para la preparacion de derivados de 2-(2-piridilmetilsulfinil)-bencimidazol opticamente activos.
CN101309917B (zh) * 2005-10-06 2013-09-11 奥斯拜客斯制药有限公司 具有增强治疗性质的胃h+，k+-atp酶氘代抑制剂
ZA200805646B (en) 2005-12-28 2009-12-30 Takeda Pharmaceutical Controlled release solid preparation
KR100758600B1 (ko) * 2006-01-05 2007-09-13 주식회사 대웅제약 란소프라졸 결정형 ａ의 제조방법
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
EP2089379A4 (en) * 2006-12-07 2010-04-21 Hetero Drugs Ltd NEW CRYSTALLINE SHAPE OF LANSOPRAZOLE
JP5366558B2 (ja) 2006-12-28 2013-12-11 武田薬品工業株式会社 口腔内崩壊性固形製剤
US8173158B2 (en) * 2007-10-12 2012-05-08 Takeda Pharmaceuticals U.S.A., Inc. Methods of treating gastrointestinal disorders independent of the intake of food
AU2008346115A1 (en) * 2007-12-18 2009-07-16 Watson Pharma Private Limited A process for preparation of stable amorphous R-lansoprazole
US20100286400A1 (en) * 2007-12-31 2010-11-11 Takeda Pharmaceutical Company Limited Crystalline solvated forms of (r)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1h-benzimidazole
EP2262790B1 (en) * 2008-03-10 2017-06-07 Takeda Pharmaceutical Company Limited Crystal of benzimidazole compound
EA021792B1 (ru) 2008-03-11 2015-09-30 Такеда Фармасьютикал Компани Лимитед Твердый препарат, растворяющийся во рту
US20110028518A1 (en) * 2008-03-18 2011-02-03 Dr. Reddy's Laboratories Ltd. Dexlansoprazole process and polymorphs
US20090263475A1 (en) * 2008-04-21 2009-10-22 Nagaraju Manne Dexlansoprazole compositions
AU2009336561A1 (en) 2008-05-14 2010-07-15 Watson Pharma Private Limited Stable R-(+)-lansoprazole amine salt and a process for preparing the same
EP2564833B1 (en) * 2008-07-28 2017-12-20 Takeda Pharmaceutical Company Limited Photostabilized pharmaceutical composition
US20100113527A1 (en) * 2008-09-30 2010-05-06 Teva Pharmaceutical Industries Ltd. Crystalline forms of dexlansoprazole
IT1391758B1 (it) * 2008-11-11 2012-01-27 Dipharma Francis Srl Procedimento per la preparazione di dexlansoprazolo amorfo
KR101321055B1 (ko) * 2008-11-14 2013-10-23 한미사이언스 주식회사 덱스란소프라졸의 신규 결정형 및 이를 포함하는 약학 조성물
IT1391776B1 (it) * 2008-11-18 2012-01-27 Dipharma Francis Srl Procedimento per la preparazione di dexlansoprazolo
IT1392813B1 (it) 2009-02-06 2012-03-23 Dipharma Francis Srl Forme cristalline di dexlansoprazolo
US20110009637A1 (en) * 2009-02-10 2011-01-13 Dario Braga Crystals of Dexlansoprazole
WO2011004387A2 (en) * 2009-06-18 2011-01-13 Matrix Laboratories Ltd Process for the preparation of dexlansoprazole polymorphic forms
IT1395118B1 (it) * 2009-07-29 2012-09-05 Dipharma Francis Srl Procedimento per la preparazione di dexlansoprazolo cristallino
US10273219B2 (en) 2009-11-12 2019-04-30 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
AU2010319349B2 (en) 2009-11-12 2015-07-16 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
CN102108076B (zh) * 2009-12-23 2014-07-23 江苏豪森医药集团有限公司 制备无定形右兰索拉唑的方法
US20130197232A1 (en) 2010-01-29 2013-08-01 Ranbaxy Laboratories Limited Process for the preparation of crystalline forms of dexlansoprazole
US20110189271A1 (en) * 2010-02-02 2011-08-04 Vishal Lad Pharmaceutical formulations of acid-labile drugs
US9085556B2 (en) 2010-03-31 2015-07-21 Ranbaxy Laboraotories Limited Salts of dexlansoprazole and their preparation
US8853411B2 (en) 2010-03-31 2014-10-07 Ranbaxy Laboratories Limited Process for the preparation of dexlansoprazole
EP2384745A3 (en) 2010-05-05 2012-01-18 Sanovel Ilac Sanayi ve Ticaret A.S. Modified release pharmaceutical compositions of dexlansoprazole
EP2384746A3 (en) 2010-05-05 2012-03-07 Sanovel Ilac Sanayi ve Ticaret A.S. Dual release oral tablet compositions of dexlansoprazole
EP2384747A3 (en) 2010-05-05 2012-01-18 Sanovel Ilac Sanayi ve Ticaret A.S. Oral Tablet Compositions Of Dexlansoprazole
US20130216617A1 (en) 2010-06-29 2013-08-22 Cadila Healthcare Limited Pharmaceutical compositions of (r)-lansoprazole
MX2013006247A (es) 2010-12-03 2014-01-31 Takeda Pharmaceutical Tableta oralmente desintegradora.
WO2012091153A2 (en) 2010-12-27 2012-07-05 Takeda Pharmaceutical Company Limited Orally disintegrating tablet
EP2663306A4 (en) * 2011-01-12 2014-01-01 Hetero Research Foundation POLYMORPHS OF DEXLANSOPRAZOLE SALTS
WO2012104805A1 (en) 2011-02-01 2012-08-09 Ranbaxy Laboratories Limited Process for the preparation of dexlansoprazole
WO2012111024A1 (en) 2011-02-18 2012-08-23 Suven Nishtaa Pharma Pvt Ltd Pharmaceutical compositions of dexlansoprazole
CA2840309A1 (en) * 2011-06-21 2012-12-27 Ranbaxy Laboratories Limited Process for the preparation of dexlansoprazole
CN102875532B (zh) * 2011-07-15 2015-05-13 上海睿智化学研究有限公司 一种(r)-兰索拉唑异丙胺盐及其晶型和制备方法
CN102875531B (zh) * 2011-07-15 2015-08-19 上海睿智化学研究有限公司 一种(r)-兰索拉唑无水晶型及其制备方法
CN102875530A (zh) * 2011-07-15 2013-01-16 上海睿智化学研究有限公司 一种(r)-兰索拉唑叔丁胺盐及其晶型和制备方法
CN102234265B (zh) * 2011-08-08 2013-11-20 天津市汉康医药生物技术有限公司 兰索拉唑化合物
JP5925318B2 (ja) 2011-11-30 2016-05-25 武田薬品工業株式会社 有核錠
KR20140113667A (ko) 2011-12-16 2014-09-24 아토픽스 테라퓨릭스 리미티드 호산구성 식도염의 치료를 위한 ｃｒｔｈ2 길항제 및 양성자 펌프 저해제의 조합
WO2013140120A1 (en) 2012-03-22 2013-09-26 Cipla Limited Glycerol solvate forms of (r) - 2 - [ [ [3 -methyl -4 (2,2, 2 - trifluoroethoxy) pyridin- 2 - yl] methyl] sulphinyl] - 1h - ben zimidazole
WO2013179194A1 (en) 2012-05-31 2013-12-05 Ranbaxy Laboratories Limited Process for the preparation of crystalline dexlansoprazole
CN103709139B (zh) * 2012-10-09 2016-12-21 上海汇伦生命科技有限公司 无水右兰索拉唑的制备方法
CN104177333A (zh) * 2013-05-24 2014-12-03 四川海思科制药有限公司 一种理化性质稳定的(r)-2-[[[3-甲基-4-(2,2,2-三氟乙氧基)-2-吡啶基]甲基]亚磺酰基]-1h-苯并咪唑
CN104650035A (zh) * 2013-11-25 2015-05-27 天津市汉康医药生物技术有限公司 右兰索拉唑倍半水合物化合物
CN103664889B (zh) * 2013-12-19 2014-11-19 悦康药业集团有限公司 一种兰索拉唑化合物
US10130618B2 (en) 2014-04-11 2018-11-20 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical combinations of dabigatran and proton pump inhibitors
WO2015155307A1 (en) 2014-04-11 2015-10-15 Sanovel Ilac Sanayi Ve Ticaret A.S. Pharmaceutical combinations of rivaroxaban and proton pump inhibitors
CN104844576B (zh) * 2015-04-28 2017-03-08 山东罗欣药业集团股份有限公司 一种兰索拉唑或右旋兰索拉唑晶型化合物及其制备方法
CN104829594A (zh) * 2015-05-15 2015-08-12 苗怡文 一种治疗胃溃疡的药物兰索拉唑化合物
CN105017218A (zh) * 2015-07-01 2015-11-04 合肥安德生制药有限公司 一种右兰索拉唑晶型及其制备方法
CN104958276A (zh) * 2015-07-30 2015-10-07 青岛蓝盛洋医药生物科技有限责任公司 一种治疗胃溃疡的药物兰索拉唑组合物胶囊
CN104997738A (zh) * 2015-08-10 2015-10-28 青岛蓝盛洋医药生物科技有限责任公司 一种治疗胃病的药物兰索拉唑组合物干混悬剂
CN105399728B (zh) * 2015-12-20 2017-11-28 寿光富康制药有限公司 一种适用于工业化生产的右兰索拉唑的处理方法
CN108164507A (zh) * 2016-12-07 2018-06-15 天津药物研究院有限公司 一种右兰索拉唑单晶及其制备方法和用途
TR201701461A2 (tr) 2017-01-31 2018-08-27 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dekslansoprazolün Enterik Kaplı Farmasötik Kompozisyonları
CN106866630B (zh) * 2017-04-01 2018-08-07 上海华源医药科技发展有限公司 一种右兰索拉唑的制备方法
CN107011329A (zh) * 2017-05-05 2017-08-04 广州大光制药有限公司 兰索拉唑一水合物晶型及其结晶制备方法
CN108794450B (zh) * 2018-07-24 2022-08-19 浙江恒康药业股份有限公司 制备无定型右旋兰索拉唑的方法
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
DK171989B1 (da) 1987-08-04 1997-09-08 Takeda Chemical Industries Ltd Fremgangsmåde til fremstilling af 2-(2-pyridylmethylsulfinyl)-benzimidazoler
DE4035455A1 (de) 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab Enantiomerentrennung
SE504459C2 (sv) 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
GB9423968D0 (en) * 1994-11-28 1995-01-11 Astra Ab Resolution
HRP960232A2 (en) 1995-07-03 1998-02-28 Astra Ab A process for the optical purification of compounds
US5840737A (en) * 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
EP0941226A1 (de) 1996-11-12 1999-09-15 Byk Gulden Lomberg Chemische Fabrik GmbH (2,3-dihydrobenzofuranyl)-thiazole als phosphodiesterasehemmer
TW385306B (en) * 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives
EP0941102A1 (en) * 1996-11-22 1999-09-15 The Procter & Gamble Company Compositions for the treatment of gastrointestinal disorders containing bismuth and nsaid
SE510666C2 (sv) 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
AU2481899A (en) 1998-01-30 1999-08-16 Sepracor, Inc. S-lansoprazole compositions and methods
EP1056456A4 (en) 1998-01-30 2006-10-25 Sepracor Inc R-LANSOPRAZOL COMPOSITIONS AND TREATMENTS THEREFOR
AU3596199A (en) * 1998-05-06 1999-11-23 Kobenhavns Universitet Treatment of celiac disease
JP3283252B2 (ja) * 1999-06-17 2002-05-20 武田薬品工業株式会社 ベンズイミダゾール化合物の結晶
TWI289557B (en) * 1999-06-17 2007-11-11 Takeda Chemical Industries Ltd A crystal of a hydrate of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
WO2001002389A1 (fr) * 1999-06-30 2001-01-11 Takeda Chemical Industries, Ltd. Cristaux de composes benzimidazole
CN1117747C (zh) * 2000-06-19 2003-08-13 中国科学院成都有机化学研究所 光学纯兰索拉唑的制备方法
US8697094B2 (en) * 2002-10-16 2014-04-15 Takeda Pharmaceutical Company Limited Stable solid preparations
EP1607395B1 (en) * 2003-03-24 2011-05-04 Eisai R&D Management Co., Ltd. Process for the preparation of amorphous rabeprazole sodium salt
US20080146615A1 (en) * 2004-12-20 2008-06-19 Dr. Reddy's Laboratories Limited Pharmaceutical Compositions Comprising Amorphous Benzimidazole Compounds
WO2006067599A2 (en) * 2004-12-23 2006-06-29 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and process of preparation thereof
US20060210637A1 (en) * 2005-03-17 2006-09-21 Qpharma, Llc Stable tablet dosage forms of proton pump inhibitors
AU2008346115A1 (en) * 2007-12-18 2009-07-16 Watson Pharma Private Limited A process for preparation of stable amorphous R-lansoprazole

Also Published As

Publication number Publication date
US8884019B2 (en) 2014-11-11
WO2004083200A1 (en) 2004-09-30
BE2014C017I2 (pt) 2019-05-21
US6939971B2 (en) 2005-09-06
US7339064B2 (en) 2008-03-04
KR20010071354A (ko) 2001-07-28
US6462058B1 (en) 2002-10-08
EP1129088A2 (en) 2001-09-05
EP2343289A1 (en) 2011-07-13
IL145996A (en) 2008-07-08
AU778820B2 (en) 2004-12-23
US7737282B2 (en) 2010-06-15
US8552198B2 (en) 2013-10-08
CN1355798A (zh) 2002-06-26
US9145389B2 (en) 2015-09-29
AR079473A2 (es) 2012-01-25
AU5247800A (en) 2001-01-09
US20120316344A1 (en) 2012-12-13
PL352193A1 (en) 2003-08-11
NO20016087L (no) 2001-12-13
EP1977751B1 (en) 2013-07-24
ZA200108331B (en) 2002-10-10
ATE391126T1 (de) 2008-04-15
WO2000078745A3 (en) 2001-07-05
AR093609A2 (es) 2015-06-10
MY125399A (en) 2006-07-31
NO321168B1 (no) 2006-03-27
KR100514204B1 (ko) 2005-09-13
AR100473A2 (es) 2016-10-12
IL145996A0 (en) 2002-07-25
HU229067B1 (en) 2013-07-29
SI1129088T1 (sl) 2008-08-31
HK1038227A1 (en) 2002-03-08
DK1129088T3 (da) 2008-06-09
US20110319450A1 (en) 2011-12-29
US20090163553A1 (en) 2009-06-25
DE60038481T2 (de) 2009-04-09
AR103295A2 (es) 2017-05-03
MXPA01012642A (es) 2002-07-22
US20150025115A1 (en) 2015-01-22
TWI289557B (en) 2007-11-11
KR20030068592A (ko) 2003-08-21
US20040048898A1 (en) 2004-03-11
EP1129088B1 (en) 2008-04-02
BR0011674A (pt) 2002-03-19
PT1977751E (pt) 2013-08-01
TWI275587B (en) 2007-03-11
ES2426985T3 (es) 2013-10-28
CN1150186C (zh) 2004-05-19
EP1977751A1 (en) 2008-10-08
AR031069A1 (es) 2003-09-10
DK1977751T3 (da) 2013-09-02
KR20010052467A (ko) 2001-06-25
US20140012006A1 (en) 2014-01-09
US20030045724A1 (en) 2003-03-06
US20080132547A1 (en) 2008-06-05
BRPI0011674B1 (pt) 2017-05-30
CA2375201C (en) 2010-02-09
PT1129088E (pt) 2008-05-05
CA2375201A1 (en) 2000-12-28
US7569697B2 (en) 2009-08-04
US8030333B2 (en) 2011-10-04
NO20016087D0 (no) 2001-12-13
HUP0201659A2 (hu) 2002-11-28
KR100537029B1 (ko) 2005-12-16
NZ515702A (en) 2003-07-25
HK1123985A1 (en) 2009-07-03
KR100407847B1 (ko) 2003-12-01
DE60038481D1 (de) 2008-05-15
US20050228026A1 (en) 2005-10-13
US6664276B2 (en) 2003-12-16
PL201068B1 (pl) 2009-03-31
US20100222391A1 (en) 2010-09-02
CY1114485T1 (el) 2017-01-25
WO2000078745A2 (en) 2000-12-28
HUP0201659A3 (en) 2003-11-28
CY1110384T1 (el) 2015-04-29
ES2300265T3 (es) 2008-06-16

Similar Documents

Publication Publication Date Title
BRPI0011674B8 (pt) cristal de (r)-2-[[[3-metil-4-(2,2,2-trifluoroetóxi)-2-piridinil]metil] sulfinil]-1h-benzimidazol, composição farmacêutica, e, uso do referido cristal
DE69003207D1 (de) Verwendung von omeprazol als antimikrobielles mittel.
CL2009000805A1 (es) Composicion farmaceutica que comprende a una sal sodica del enantiomero (-) de 5-metoxi-2[[(4-metoxi-3,5-dimetil-2-piridinil)metil]sulfinil]-1h-bencimidazol ((-)-omeprazol); y su uso en la inhibicion de la secrecion de acido gastrico y para tratar enfermedades inflamatorias gastrointestinales. (divisional solicitud 3570-00).
ATE291901T1 (de) Neue omeprazole und (s)-omeprazole zusammensetzung
AR013350A1 (es) Sal de sodio de omeprazol forma b, proceso para su preparacion, formulacion farmaceutica, y uso de dicha sal para la fabricacion de medicamentos.
DE69611315D1 (de) 5-Substituierte-3-(1,2,3,6-Tetrahydropyridin-4-yl) und 3-(Piperidin-4-yl)-1H-indole: 5-HT1F Agonisten
DE60035682D1 (de) Di-aryl-säurederivate als ppar rezeptor liganden
LV10268A (lv) Terapeitiski aktivs benzimidazols un ta iegusanas panemiens
TR199901643T1 (xx) Yeni y�ntem.
NO20024823D0 (no) Medisinske preparater inneholdende camptothecin-derivat og pH regulerende middel
BR0012591A (pt) Agente profilático ou terapêutico para câncer
IT1271434B (it) Composizione farmaceutica avente attivita' antiasmatica
BR0005039A (pt) Antagonistas do receptor nk-1 e eletriptano para o tratamento da enxaqueca
AU4261196A (en) Use of 2-(4-(azolylbutyl)piperazinyl-(methyl)benzimidazole derivatives for preparing drugs for treating or preventing asthma

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP)

Free format text: ALTERADO DE: TAKEDA CHEMICAL INDUSTRIES, LTD.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DA INT.CL: C07D 401/12

Ipc: C07D 401/12 (2010.01), A61P 1/04 (2010.01), A61P 1

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 13 E 25 DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/06/2000 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 15/06/2020